Rivaroxaban for preventing adverse outcomes after acute management of acute coronary

Committee was persuaded that the issue of generalisability was similar across all trials in this condition, and concluded that the results of ATLAS-ACS 2-TIMI 51 were relevant to routine clinical practice. 4.5 The Committee considered the results of the ATLAS-ACS 2-TIMI 51 trial. The Committee noted that the company had presented clinical-effectiveness results for the overall trial population and also for a post hoc subgroup analysis of patients with elevated cardiac biomarkers (STEMI and NSTEMI) and no history of a stroke or TIA (80% of the total trial population). The Committee was aware from the company that this post hoc subgroup analysis was carried out at the request of the European Medicines Agency (EMA). The Committee noted that this post hoc subgroup analysis (referred to as the licensed population by the company) provided efficacy results that tended to be more favourable to rivaroxaban than the results from the overall trial population. However, it acknowledged that these differences were unlikely to be sufficiently large as to have an impact on the overall decision as to whether rivaroxaban was clinically and cost effective in its licensed indication. 4.6 The Committee discussed the numerical inconsistencies between the 2 dose groups in the trial
